Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Life Technologies

(

LIFE

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Life Technologies rose 81 cents (1.7%) to $47.88 on average volume. Throughout the day, 1.5 million shares of Life Technologies exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in a price between $47.02-$47.99 after having opened the day at $47.16 as compared to the previous trading day's close of $47.07. Other companies within the Drugs industry that increased today were:

MEI Pharma

(

MEIP

), up 22%,

Cell Therapeutics

(

CTIC

), up 9.7%,

Novogen

(

NVGN

), up 8%, and

Prima Biomed Ltd. ADR

(

PBMD

), up 7.7%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Life Technologies Corporation operates as a global life sciences company. Life Technologies has a market cap of $8.25 billion and is part of the

health care

sector. The company has a P/E ratio of 19.4, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 21% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Life Technologies a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Life Technologies as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null